NCT05408026 2023-01-27
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Alliance Foundation Trials, LLC.
Phase 1/2 Withdrawn
Clinical Trials
4 trialsNCT03617484 2020-06-22
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT00706953 2015-04-06
A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Withdrawn
NCT01266811 2013-01-28
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Centocor, Inc.
Phase 3 Withdrawn